Literature DB >> 19108974

Feasibility of magnetic resonance imaging-guided high intensity focused ultrasound therapy for ablating uterine fibroids in patients with bowel lies anterior to uterus.

Lian Zhang1, Wen-Zhi Chen, Yin-Jiang Liu, Xiao Hu, Kun Zhou, Li Chen, Song Peng, Hui Zhu, Hui-Ling Zou, Jin Bai, Zhi-Biao Wang.   

Abstract

PURPOSE: To prospectively evaluate the feasibility of magnetic resonance (MR) imaging-guided high intensity focused ultrasound (HIFU) therapeutic ablation of uterine fibroids in patients with bowel lies anterior to uterus.
MATERIALS AND METHODS: Twenty-one patients with 23 uterine fibroids underwent MR imaging-guided high intensity focused ultrasound treatment, with a mean age of 39.4+/-6.9 (20-49) years, with fibroids average measuring 6.0+/-1.6 (range, 2.9-9.5)cm in diameter. After being compressed with a degassed water balloon on abdominal wall, MR imaging-guided high intensity focused ultrasound treatment was performed under conscious sedation by using fentanyl and midazolam. This procedure was performed by a Haifu JM focused ultrasound tumour therapeutic system (JM2.5C, Chongqing Haifu Technology Co., Ltd., China), in combination with a 1.5-Tesla MRI system (Symphony, Siemens, Germany), which provides real-time guidance and control. Contrast-enhanced MR imaging was performed to evaluate the efficacy of thermal ablation immediately and 3 months after HIFU treatment. The treatment time and adverse events were recorded.
RESULTS: The mean fibroid volume was 97.0+/-78.3 (range, 12.7-318.3)cm(3). According to the treatment plan, an average 75.0+/-11.4% (range, 37.8-92.4%) of the fibroid volume was treated. The mean fibroid volume immediately after HIFU was 109.7+/-93.1 (range, 11.9-389.6)cm(3), slightly enlarged because of edema. The average non-perfused volume was 83.3+/-71.7 (range, 7.7-282.9)cm(3), the average fractional ablation, which was defined as non-perfused volume divided by the fibroid volume immediately after HIFU treatment, was 76.9+/-18.7% (range, 21.0-97.0%). There were no statistically significant differences between the treatment volume and the non-perfused volume. Follow-up magnetic resonance imaging (MRI) at 3 months obtained in 12 patients, the fibroid volume decreased by 31.4+/-29.3% (range, -1.9 to 60.0%) in average, with paired t-test showing a statistically significant reduction (P=0.002). The mean treatment time for ablating the average 83.3+/-71.7 (range, 7.7-282.9)cm(3) of fibroid volume was 2.5+/-1.4h (range, 27-390min) in this study, which was relatively short and acceptable to patient and therapist. Four patients experienced mild skin burn (two with skin redness, two with blisters), the skin burn subsided within approximately 2 days. No other adverse events were observed.
CONCLUSIONS: After the bowel was compressed with a degassed water balloon, MR imaging-guided high intensity focused ultrasound treatment is safe and feasible in ablating uterine fibroids in patients with bowel lies anterior to uterus. Copyright (c) 2008 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2008        PMID: 19108974     DOI: 10.1016/j.ejrad.2008.11.002

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  26 in total

Review 1.  MR-guided focused ultrasound surgery, present and future.

Authors:  David Schlesinger; Stanley Benedict; Chris Diederich; Wladyslaw Gedroyc; Alexander Klibanov; James Larner
Journal:  Med Phys       Date:  2013-08       Impact factor: 4.071

2.  Is MR-guided High-intensity Focused Ultrasound a Feasible Treatment Modality for Desmoid Tumors?

Authors:  Raffi S Avedian; Rachelle Bitton; Garry Gold; Kim Butts-Pauly; Pejman Ghanouni
Journal:  Clin Orthop Relat Res       Date:  2016-03       Impact factor: 4.176

Review 3.  Interventional radiology of the adrenal glands: current status.

Authors:  Anna Maria Ierardi; Mario Petrillo; Francesca Patella; Pierpaolo Biondetti; Enrico Maria Fumarola; Salvatore Alessio Angileri; Filippo Pesapane; Antonio Pinto; Gianlorenzo Dionigi; Gianpaolo Carrafiello
Journal:  Gland Surg       Date:  2018-04

4.  Acceleration of ultrasound thermal therapy by patterned acoustic droplet vaporization.

Authors:  Oliver D Kripfgans; Man Zhang; Mario L Fabiilli; Paul L Carson; Frederic Padilla; Scott D Swanson; Charles Mougenot; J Brian Fowlkes; Charles Mougenot
Journal:  J Acoust Soc Am       Date:  2014-01       Impact factor: 1.840

Review 5.  Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU) Treatment of Symptomatic Uterine Fibroids: An Evidence-Based Analysis.

Authors:  G Pron
Journal:  Ont Health Technol Assess Ser       Date:  2015-03-01

Review 6.  High-intensity focused ultrasound tumor ablation: review of ten years of clinical experience.

Authors:  Lian Zhang; Zhi-Biao Wang
Journal:  Front Med China       Date:  2010-08-10

7.  Mid-term clinical efficacy of a volumetric magnetic resonance-guided high-intensity focused ultrasound technique for treatment of symptomatic uterine fibroids.

Authors:  Marlijne E Ikink; Marianne J Voogt; Helena M Verkooijen; Paul N M Lohle; Karlijn J Schweitzer; Arie Franx; Willem P Th M Mali; Lambertus W Bartels; Maurice A A J van den Bosch
Journal:  Eur Radiol       Date:  2013-06-21       Impact factor: 5.315

8.  Tumor boundary detection in ultrasound imagery using multi-scale generalized gradient vector flow.

Authors:  Yi Le; Xianze Xu; Li Zha; Wencheng Zhao; Yanyan Zhu
Journal:  J Med Ultrason (2001)       Date:  2014-08-05       Impact factor: 1.314

Review 9.  Image-guided percutaneous ablation therapies for local recurrences of thyroid tumors.

Authors:  C M Pacella; E Papini
Journal:  J Endocrinol Invest       Date:  2013-01       Impact factor: 4.256

10.  Boosting high-intensity focused ultrasound-induced anti-tumor immunity using a sparse-scan strategy that can more effectively promote dendritic cell maturation.

Authors:  Fang Liu; Zhenlin Hu; Lei Qiu; Chun Hui; Chao Li; Pei Zhong; Junping Zhang
Journal:  J Transl Med       Date:  2010-01-27       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.